Literature DB >> 23188661

Natural course of noncurative endoscopic resection of differentiated early gastric cancer.

J Y Ahn1, H Y Jung, J Y Choi, M Y Kim, J H Lee, K S Choi, D H Kim, K D Choi, H J Song, G H Lee, J H Kim, Y S Park.   

Abstract

BACKGROUND AND STUDY AIMS: Following noncurative endoscopic resection of early gastric cancer (EGC), the patient should be observed when the underlying disease is severe, the patient is elderly, or the patient refuses further treatment. The aim of this study was to analyze the clinical outcomes of patients with differentiated EGC who underwent noncurative endoscopic resection without additional treatment. PATIENTS AND METHODS: Included patients underwent noncurative endoscopic resection for differentiated EGC without additional treatment at the Asan Medical Center between July 1994 and January 2009. Clinical and oncological outcomes were analyzed.
RESULTS: A total of 159 patients were included in the analysis. The median follow-up period was 33 months (interquartile range [IQR] 22 - 52 months). In total, 40 patients died (25.2 %) - 3 due to stomach cancer, 34 due to other causes, and 3 from unknown causes; the median survival time after endoscopic treatment for these patients was 27.5 months (IQR 13.8 - 48.3 months). Multivariate analysis showed that the rates of underlying disease (P < 0.001) and lymphovascular invasion (P = 0.005) were higher among the 40 patients who died than among the 119 survivors. The overall 3-  and 5-year survival rates were 82.9 % and 77.1 %, respectively; the rates of the patients with lymphovascular invasion were 61.9 % and 42.4 %, respectively, and the rates of patients without lymphovascular invasion were 86.1 % and 81.8 %, respectively (P < 0.001).
CONCLUSIONS: Additional treatment provides fewer benefits to patients who do not have long life expectancies. Additional surgery can be considered for patients with lymphovascular invasion because of its high mortality rate; however, the benefits and risks of surgery should be considered carefully. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23188661     DOI: 10.1055/s-0032-1325676

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  14 in total

1.  Optimal management for patients not meeting the inclusion criteria after endoscopic submucosal dissection for gastric cancer.

Authors:  Takahiro Toyokawa; Masaichi Ohira; Hiroaki Tanaka; Hiroaki Minamino; Katsunobu Sakurai; Yasuaki Nagami; Naoshi Kubo; Atsushi Yamamoto; Koji Sano; Kazuya Muguruma; Kazunari Tominaga; Hiroko Nebiki; Yoshito Yamashita; Tetsuo Arakawa; Kosei Hirakawa
Journal:  Surg Endosc       Date:  2015-10-13       Impact factor: 4.584

2.  Risk stratification and management of non-curative resection after endoscopic submucosal dissection for early gastric cancer.

Authors:  Jae Pil Han; Su Jin Hong; Hee Kyung Kim; Yun Nah Lee; Tae Hee Lee; Bong Min Ko; Joo Young Cho
Journal:  Surg Endosc       Date:  2015-04-01       Impact factor: 4.584

3.  Can further gastrectomy be avoided in patients with incomplete endoscopic resection?

Authors:  Hee Sung Kim; Ji Yong Ahn; Seon Ok Kim; Byung Sik Kim
Journal:  Surg Endosc       Date:  2017-04-19       Impact factor: 4.584

4.  Additional surgery for non-curative resection after endoscopic submucosal dissection for gastric cancer: a retrospective analysis of 200 cases.

Authors:  Hideki Sunagawa; Takahiro Kinoshita; Akio Kaito; Hidehito Shibasaki; Kazuhiro Kaneko; Atsushi Ochiai; Atsushi Ohtsu; Toshirou Nishida
Journal:  Surg Today       Date:  2016-05-18       Impact factor: 2.549

5.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

Review 6.  Treatment modalities for early gastric cancer.

Authors:  Jesús Espinel; Eugenia Pinedo; Vanesa Ojeda; Maria Guerra Del Rio
Journal:  World J Gastrointest Endosc       Date:  2015-09-10

7.  Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.

Authors:  Bin Wu; Te Li; Jian Cai; Yuejuan Xu; Gang Zhao
Journal:  BMC Cancer       Date:  2014-12-19       Impact factor: 4.430

8.  Lymph node metastasis can be determined by just tumor depth and lymphovascular invasion in early gastric cancer patients after endoscopic submucosal dissection.

Authors:  Atsushi Goto; Jun Nishikawa; Eizaburou Hideura; Ryo Ogawa; Misato Nagao; Sho Sasaki; Ryo Kawasato; Shinichi Hashimoto; Takeshi Okamoto; Hiroyuki Ogihara; Yoshihiko Hamamoto; Isao Sakaida
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-12       Impact factor: 2.566

Review 9.  Evaluation and Management of Gastric Superficial Neoplastic Lesions.

Authors:  Pedro Pimentel-Nunes; Diogo Libânio; Mário Dinis-Ribeiro
Journal:  GE Port J Gastroenterol       Date:  2016-11-01

Review 10.  Long-term outcome of extended endoscopic submucosal dissection for early gastric cancer with differentiated histology.

Authors:  Ji Yong Ahn; Hwoon-Yong Jung
Journal:  Clin Endosc       Date:  2013-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.